Investing in chronic disease follow-up in West Africa.
Blâdemy connects patients and caregivers where the network fails: a market set to more than double by 2050, technology ready for it, a clinical pilot prepared with public stakeholders.
Diabetes is growing faster than the number of doctors.
Chronic patients often live far from the nearest specialist, and far from the network. Solutions that require a permanent connection stop where the need is greatest.
- Africa · adults with diabetes, from 2024 to 2050
- 25 → 60 M
- Africa · do not know they have it
- 4 in 5
- Africa · diabetes-related deaths in 2024
- 216,000
- Côte d’Ivoire · people with diabetes
- 529,200
- Côte d’Ivoire · people with hypertension
- 4.5 M
A platform, not a device.
- 01
A growing need
The number of people with diabetes in Africa will more than double by 2050; the number of specialists will not.
- 02
Offline first
Blâdemy works without a network: it goes where cloud-dependent solutions cannot.
- 03
Three audiences, three revenues
Patients, facilities and institutions each pay for what they get, with plans suited to mobile payment.
- 04
Medical credibility
An endocrinologist co-founder, a pilot at the Abidjan Military Hospital, a national programme alongside us.
- 05
Proven hardware
The devices come from established manufacturers; Blâdemy’s value lies in the software, the follow-up and the data.
- 06
Replicable
The same model extends from Côte d’Ivoire to the rest of West Africa.
- 07
Sovereign data
Hosted in the patients’ country, under its law: the condition for working with governments and national programmes.
A platform today, a data asset tomorrow.
Every patient followed adds to rare data: the real life of chronic diseases in West Africa, measured at home and over time.
- Phase 1 · until 2027
The pilot and the technology
The connected kit, the app that works without a network and the caregiver dashboard, put to the test by a 200-patient clinical pilot in 2027, with the Abidjan Military Hospital and the PNLMM / PMNT.
- Phase 2 · from 2028
A real-world data asset
Blood glucose, blood pressure and uric acid measured at home, followed month after month and linked to the caregivers’ follow-up: sovereign data, collected with patients’ consent and anonymised, on a population still rarely present in health data, serving research and public health.
From an award to a clinical pilot.
- 2022 Arthur Yoffoua wins MTN Y’ello Startup.
- September 2025 Partnership with FasterCapital, EquityPilot programme.
- October – November 2025 Pan-African and Ivorian press cover the project.
- 2026Goal Kits finalised and institutional agreements signed.
- Q2 – Q4 2027Goal Official pilot test: 200 patients, with the Abidjan Military Hospital and the PNLMM / PMNT.
- Q2 – Q4 2027Goal Data/AI platform finalised: ISO 27001 and ISO 13485 certifications, a dedicated DPO, regular security audits.
- 2028Goal Real-world data collection in Côte d’Ivoire.
- From 2029Goal International expansion, starting with Senegal and Ghana: 15,000 active users in the first year.
A full local team, international technical expertise, scientific governance.
Leadership and operations
-
Arthur Yoffoua CEO and co-founder -
Dr Jean-Brice Ahoussi Medical director and co-founder
-
David Siegrist Chief financial officer -
Venceslas Aka Sales director -
Maxime-Olivier Baudoua-Yao Administration and finance manager
Technology, data and AI
-
Adama Ouattara Chief technology officer -
Juned Dosani Full-stack lead developer
Scientific governance →
-
Pr Alexandre Mebazaa Scientific patron -
Dr Kouakou K. Ernest Principal investigator
Funding clinical validation and roll-out.
The funds raised go to producing the kits, completing clinical validation and rolling Blâdemy out in Côte d’Ivoire, then West Africa. Amount, instrument and terms are in the investor deck, sent on request.